Pappas Capital LLC
10/17/2018 | Press release | Archived content
CuraSen Therapeutics Announces $54.5 Million Series A Financing
News | 10. 17. 2018
CuraSen Therapeutics
SAN MATEO, Calif., Oct. 17, 2018 -- CuraSen Therapeutics, Inc., a privately held biotechnology company focused on developing therapies to treat neurodegenerative diseases, today announced the closing of a $54.5 million Series A financing. Led by New Leaf Venture Partners, the investor syndicate includes Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation - JJDC, Inc. (JJDC), and Pappas Capital. CuraSen is developing small molecule drugs targeting a novel mechanism in the brain to alleviate disabling symptoms and modify disease pathology in patients who suffer from less common (orphan) neurodegenerative disorders as well as Parkinson's Disease and Alzheimer's Disease.
Pappas Capital LLC published this content on October 17, 2018, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 09:59 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]